The effect of moxonidine on plasma lipid profile and on LDL subclass distribution

Journal of Human Hypertension

Volumn 13, Issue 11, 1999, Pages 781-785

  Elisaf, Moses S ^a   Petris, C ^b   Bairaktari, E ^b   Karabina, S A ^b   Tzallas, C ^b   Tselepis, A ^b   Siamopoulos, K C ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b NONE

Author keywords

LDL oxidation susceptibility; LDL subclass pattern; Moxonidine; Plasma lipid profile; Sympathetic nervous system

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; COPPER; IMIDAZOLINE RECEPTOR; LIPID; LOW DENSITY LIPOPROTEIN; MOXONIDINE; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADRENERGIC SYSTEM; ADULT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MALE; PHENOTYPE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032713551     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000835     Document Type: Conference Paper

References (31)

1. Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med 1988; 148: 1280-1288.
2. Ames RP. The effects of antihypertensive drugs or serum lipids and lipoproteins. 1. Diuretics. Drugs 1986; 32: 260-278.
3. Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and levels. Eur Heart J 1992; 13 (Suppl G): 5-9.
4. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996; 77: 12B-16B.
5. Superko HR, Haskell WL, Krauss RM. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis 1993; 101: 1-8.
6. Superko HR, Wood PD, Krauss RM. Effect of alpha-and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses and postprandial lipemia. Am J Med 1989; 86 (Suppl 1B): 26-29.
7. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
8. MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective, observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
9. Head GA. Importance of imidazoline receptors in the cardiovascular actions of centrally acting antihypertensive agents. Ann NY Acad Sci 1995; 763: 531-540.
10. Prichard BNC, Graham BR. The use of moxonidine in the treatment of hypertension. J Hypertens 1997; 15 (Suppl 1): S47-S55.
11. Morris STW, Reid JL. Moxonidine: a review. J Hum Hypertens 1997; 11: 629-635.
12. Chrisp P, Faulds D. Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension. Drugs 1992; 44: 993-1012.
13. Kaan EC et al. Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995; 5 (Suppl 1): 19-27.
14. Michel MG, Ernsberger P. Keeping an eye on the I site: imidazoline-preferring receptors. Trends Pharmacol Sci 1992; 13: 369-370.
15. De Graaf J et al. Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11: 298-306.
16. 1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995; 15: 1764-1773.
17. Friedewald, WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge. Clin Chem 1972; 18: 499-502.
18. Campos H et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992; 12: 187-195.
19. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.
20. Krentz AJ, Evans AJ. Selective imidazoline receptor agonists for metabolic syndrome. Lancet 1998; 351: 152-153.
21. Lardinois CK, Johns JP. Cardiac drug effects on lipids. Curr Opin Lipidol 1992; 5: 274-278.
22. Houston MC et al. The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J 1990; 120: 172-179.
23. Griffin BA et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241-254.
24. Keidar S et al. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994; 107: 71-84.
25. Kirch H, Hutt H-J, Plänitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990; 30: 1088-1095.
26. Mitrovic V, Patyna W, Hüting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5: 967-972.
27. Mitrovic V et al. Haemodynamic and neurohormonal effects of a single oral dose of the imidazoline I receptor agonist moxonidine in patients with idiopathic dilated cardiomyopathy and heart failure. Eur J Clin Res 1996; 8: 149-161.
28. Lesnik P et al. Impact of a combination of a calcium antagonist and a β-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. Arterioscler Thromb Vasc Biol 1997; 17: 979-988.
29. Jenkins RR, Del-Signore CM, Sauer P, Skelly C. The effect of beta blocking drugs on lipid peroxidation in rat heart in vitro. Lipids 1992; 27: 539-542.
30. Yue TL et al. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 1993; 22: 922-928.
31. Lupo E, Locher R, Weisser B, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with a-tocopherol. Biochem Biophys Res Com 1994; 203: 1803-1808.